8-KEarnings & ResultsExhibits & Filings

JOHNSON & JOHNSON 8-K Report, Financial Results (Jul 16, 2019)

Filed July 16, 2019For Securities:JNJ

Summary

Johnson & Johnson (JNJ) filed an 8-K on July 16, 2019, reporting its second-quarter results for the period ended June 30, 2019. The filing includes a press release and supplementary financial data, outlining the company's sales and earnings performance. Investors should review these results to understand the company's operational performance and financial health during the quarter. Key metrics such as revenue growth, profitability, and segment performance are crucial for assessing JNJ's current trajectory and future outlook. While specific figures are detailed in the attached exhibits, the primary purpose of this 8-K is to officially disseminate the Q2 2019 financial outcomes. This report serves as a critical update for shareholders and potential investors, providing the latest financial insights from one of the world's largest healthcare companies. The information here is essential for making informed investment decisions regarding JNJ.

Key Highlights

  • 1Johnson & Johnson announced its second-quarter financial results for the period ending June 30, 2019.
  • 2The 8-K filing includes a press release detailing the company's sales and earnings for Q2 2019.
  • 3Supplementary sales data and condensed consolidated statements of earnings are provided for the second quarter.
  • 4This filing serves as an official disclosure of JNJ's financial performance during the reporting period.
  • 5Investors can access detailed operational and financial condition information through the attached exhibits.
  • 6The report is critical for assessing JNJ's recent financial health and performance trends.

Frequently Asked Questions

The main purpose of this 8-K filing is to formally announce and provide details on Johnson & Johnson's sales and earnings for the second quarter ended June 30, 2019. It includes a press release and supplementary financial data for investors.

The specific financial results, including sales and earnings, are detailed in the press release (Exhibit 99.15) and the Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings (Exhibit 99.2O) attached to this 8-K filing.

Investors should look for key metrics such as total sales, sales by segment (Pharmaceutical, Medical Devices, Consumer Health), earnings per share (EPS), net income, and any year-over-year growth rates to assess Johnson & Johnson's performance during the second quarter of 2019.

This 8-K specifically focuses on the financial results for the second quarter of 2019. While it provides insights into the company's financial condition and operations through sales and earnings data, it is not a comprehensive update on all business segments or strategic initiatives. For broader operational details, investors should refer to other filings and company communications.